Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

BACKGROUND: Upfront cytoreductive nephrectomy (CN) is no longer the standard of care for patients with metastastic renal cell carcinoma (mRCC) with intermediate or poor prognosis according to the International mRCC Database Consortium categories. OBJECTIVE: To investigate indications for CN followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fransen van de Putte, Elisabeth E., van den Brink, Luna, Mansour, Mohamed A., van der Mijn, Johannes C., Wilgenhof, Sofie, van Thienen, Johannes V., Haanen, John B.A.G., Boleti, Ekaterini, Powles, Thomas, Zondervan, Patricia J., Graafland, Niels M., Bex, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Kidney Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485779/
https://www.ncbi.nlm.nih.gov/pubmed/37693729
http://dx.doi.org/10.1016/j.euros.2023.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485779/
https://www.ncbi.nlm.nih.gov/pubmed/37693729
http://dx.doi.org/10.1016/j.euros.2023.07.002

Ejemplares similares